
|Podcasts|June 25, 2020
ARVO 2020: Two-year anatomical outcomes of FAc in DME patients
Author(s)Alex Delaney-Gesing
Advertisement
Victor Gonzalez, MD, speaks with Ophthalmology Times® David Hutton on the highlights of his presentation regarding "Two-year outcomes from the PALADIN Phase 4 study: Anatomic/functional changes and reduced treatment frequency associated with 0.19 mg of fluocinolone acetonide implant (FAc) with persistent or recurrent diabetic macular edema," during the 2020 Association for Research in Vision and Ophthalmology (ARVO) virtual meeting.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA update: Outlook Therapeutics receives CRL for resubmitted ONS-5010 BLA
2
FDA approvals in 2025: What changed and why it matters for ophthalmologists
3
PRIMAvera study: Central vision improvement with subretinal implant
4
What changed in glaucoma care in 2025: Surgeon perspective
5











































